Abstract
The pharmaceutical industry is going through a period of enormous upheaval, as new sciences, technologies and commercial pressures reshape the way in which it performs research and development. PwC Consulting estimates that the top 20 companies will each need to launch between four and six times the number of drugs they currently produce, as well as improving the quality of those drugs, merely to maintain shareholder returns. This has huge implications for pharmacovigilance departments. More drugs means more trials, more patients and — of course — more safety reports for evaluation. The pharmacovigilance teams in most big companies are ill prepared for this transition being already stretched to the limit. But as demand for patients to participate in clinical trials increases — with shorter development times, higher success rates in discovery and greater productivity — so companies with a poor reputation for safety will suffer.
What is it then that companies should be doing to remain compliant and be seen to be safe in the eyes of the consumer? Can pharmacoepidemiology support both molecules in the marketplace as well as those in research and development and what is really needed to enable this?
Key to success will be the ability to capture, analyse and evaluate data (from disparate sources) in real time and to make rapid decisions on the appropriate course of action. Putting better structures, processes and technological platforms in place to cope with a big increase in throughput is only a short-term solution yet is it enough to fulfil the objective in the long-term of ensuring compliance and patient safety?
References
Pharma 2005 Series. An industrial revolution in R&D. PricewaterhouseCooper report 1998 [online]. Available from URL: http://www.pwcconsulting.com/pharma [Accessed 2002 May 28]
Pharma 2005 Series. Silicon rally: the race to e-R&D. PricewaterhouseCooper report 1999 [online]. Available from URL: http://www.pwcconsulting.com/pharma [Accessed 2002 May 28]
Peck C. Drug development: improving the process. Food Drug Law J 1997; 52(2): 163–7
Peck BF, O’Neil R. Oral presentation on ECPM. 1996 Oct; Basel, Switzerland
FDA Center for Drug Evaluation and Research (CDER). 1998 report to the nation [online]. Available from URL: http://www.fda.gov/dcer/reports/rptntn98.pdf [Accessed 2002 May 27]
Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997 Jan 22-29; 277(4): 307–11
Managing the risks from medical product use: creating a risk management framework. US Department of Health and Human Services, FDA, May 1999
Davenport HW. Gastric mucosal injury by fatty and acetylsalicylic acids. Gastroenterology 1964; 46: 245–53
Acknowledgements
This review was originally published in the European Pharmaceutical Review 2000; 5 (2): 7-10 and has been reproduced with kind permission of the European Pharmaceutical Review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Peachey, J. From Pharmacovigilance to Pharmacoperformance. Drug-Safety 25, 399–405 (2002). https://doi.org/10.2165/00002018-200225060-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200225060-00003